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Abstract
Background: Cameroon is one of 12 African countries that bear most of the global burden of
yellow fever. In 2002 the country developed a five-year strategic plan for yellow fever control,
which included strategies for prevention as well as rapid detection and response to outbreaks when
they occur. We have used data collected by the national Expanded Programme on Immunisation
to assess the progress made and challenges faced during the first four years of implementing the
plan.
Methods: In January 2003, case-based surveillance of suspected yellow fever cases was instituted
in the whole country. A year later, yellow fever immunisation at nine months of age (the same age
as routine measles immunisation) was introduced. Supplementary immunisation activities (SIAs),
both preventive and in response to outbreaks, also formed an integral part of the yellow fever
control plan. Each level of the national health system makes a synthesis of its activities and sends
this to the next higher level at defined regular intervals; monthly for routine data and daily for SIAs.
Results: From 2004 to 2006 the national routine yellow fever vaccination coverage rose from
58.7% to 72.2%. In addition, the country achieved parity between yellow fever and measles
vaccination coverage in 2005 and has since maintained this performance level. The number of
suspected yellow fever cases in the country increased from 156 in 2003 to 859 in 2006, and the
proportion of districts that reported at least one suspected yellow fever case per year increased
from 31.4% to 68.2%, respectively. Blood specimens were collected from all suspected cases
(within 14 days of onset of symptoms) and tested at a central laboratory for yellow fever IgM
antibodies; leading to confirmation of yellow fever outbreaks in the health districts of Bafia, Méri
and Ntui in 2003, Ngaoundéré Rural in 2004, Yoko in 2005 and Messamena in 2006. Owing to
constraints in rapidly mobilising the necessary resources, reactive SIAs were only conducted in
Bafia and Méri several months after confirmation of the outbreak. In both districts, a total of 60,083
people (representing 88.2% of the 68,103 targeted) were vaccinated. Owing to the same
constraints, SIAs were not conducted promptly in response to the outbreaks in Ntui, Ngaoundéré
Rural, Yoko and Messamena. However, these four and two other health districts at high risk of
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yellow fever outbreaks (i.e. Maroua Urban and Ngaoundéré Urban) conducted preventive SIAs in
November 2006, vaccinating a total of 752,195 people (92.8% of target population). In both the
reactive and preventive SIAs, the mean wastage rates for vaccines and injection material were less
than 5% and there was no report of a serious adverse event following immunisation.
Conclusion: Amidst other competing health priorities, over the past four years Cameroon has
successfully planned and implemented evidence-based strategies for preventing yellow fever
outbreaks and for detecting and responding to the outbreaks when they occur. In order to sustain
these initial successes, the country will have to attain and sustain high routine vaccination coverage
in each successive birth cohort in every district. This would require fostering and sustaining high-
level political commitment, improving the planning and monitoring of immunisation services at all
levels, adequate community mobilisation, and efficient coordination of current and future
immunisation partners.
Background
Yellow fever, which has caused devastating epidemics for
centuries [1-3], continues to cause severe morbidity and
mortality in Africa [4-6] despite the availability of an effec-
tive vaccine for the past 70 years [7]. The viral haemor-
rhagic disease is propagated in Africa by infected
mosquitoes [8]. Aedes aegypti is the intermediary in the
urban human-to-human cycle of transmission and vari-
ous Aedes species are intermediaries in the jungle monkey-
to-monkey cycle, with inadvertent human insertion into
that cycle. The World Health Organization (WHO) esti-
mates that the disease causes 200,000 cases and up to
30,000 deaths each year in the continent [9]. Most of
these cases and deaths occur in 12 countries, including
Cameroon [10]. Cameroon is situated in central Africa at
the end of the Gulf of Guinea, between latitudes 2° and
13° north of the Equator and longitudes 9° and 16° east
of the Greenwich Meridian. The country, whose current
population is estimated at 18 million inhabitants of
whom 46% live in urban areas, conducted periodic mass
preventive yellow fever vaccination campaigns for about
three decades beginning in the early 1930s [11]. These
regular mass campaigns led to a rapid reduction in suscep-
tible individuals and, consequently, the yellow fever bur-
den in the country. Within two decades of cessation of the
preventive vaccination campaigns, Cameroon started
experiencing serious yellow fever epidemics [12,13], most
of which remained unknown [14] owing to a weak disease
surveillance system. In September-December 1990 during
one epidemic in the Far North Province of the country,
182 cases (with 69% case-fatality rate) were reported [13],
but it is estimated that up to 20,000 cases may have
occurred during that epidemic [15]. Building upon expe-
rience gained in conducting high-quality polio eradica-
tion and measles elimination activities [16-19], in 2002
Cameroon developed a five-year (2003–2007) strategic
plan for yellow fever control. In this report, we present
progress and challenges of implementing the plan during
its first four years of existence.
Methods
The Cameroon government (through the Ministry of Pub-
lic Health) planned and implemented the yellow fever
control activities, with support from development part-
ners including the Global Alliance for Vaccines and
Immunization (GAVI Alliance), WHO and the United
Nations Children Fund (UNICEF). The control activities
involve the prevention of yellow fever outbreaks (through
routine vaccination and regular preventive mass vaccina-
tion campaigns) and case-based yellow fever surveillance
with laboratory confirmation and rapid mass vaccination
response when an outbreak occurs [20].
The achievement and maintenance of high yellow fever
vaccination coverage among infants through routine
health services is an essential component of the plan. In
2004, routine yellow fever vaccination with one dose of
the 17D yellow fever vaccine at nine months of age (the
same age as the measles vaccine) was introduced in the
whole country under the Expanded Programme on
Immunisation (EPI). Routine childhood immunisation is
offered in both public and private health centres in the
country. Each health centre records vaccination acts in
childhood vaccination cards and vaccination registers. At
the beginning of each month, health centres compile the
number of children who have received vaccines (includ-
ing the yellow fever vaccine) and send the synthesis to the
lead health centre in the health area. These synthesise the
monthly vaccination acts for the health area and forward
the reports to the district health service by the fifth day of
each month. The district service makes a synthesis of vac-
cinations conducted in the health district and forwards
this to the provincial level by the tenth day of each month,
together with copies of the health area reports. The pro-
vincial level in turn makes its own synthesis and sends this
to the Central Technical Group of the EPI by the fifteenth
day of each month, together with copies of district synthe-
ses that were used to compile the provincial report. The
central level then makes a synthesis of district, provincial
and national coverage. Each higher level sends feedbackBMC Medicine 2008, 6:3 http://www.biomedcentral.com/1741-7015/6/3
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on performance to the lower level that provided it with
data. The performance of routine yellow fever immunisa-
tion is assessed by the yellow fever vaccination coverage
achieved and the coverage gap between the yellow fever
and measles vaccine. While childhood immunisation is
considered the long-term strategy for yellow fever control,
several decades are needed to reduce susceptibility in all
age groups. Therefore, to rapidly reduce susceptibility and
prevent outbreaks in the meantime, yellow fever control
activities in Cameroon include preventive mass vaccina-
tion campaigns in high-risk health districts. During the
training of both vaccinators and supervisors for the cam-
paigns, the procedures, tools and importance of data
management during a mass vaccination campaign were
explained. During the campaigns, the head of health area
synthesises data from vaccination posts under their juris-
diction daily, identify problems and take appropriate
action, and forward the syntheses to the district health
service. The district makes its own synthesis and sends this
to the provincial level, which in turn makes its own syn-
thesis and forwards this to the central level. The central
command post makes a daily synthesis of the campaign
coverage and sends this feedback to the provincial level,
which in turn sends feedback to the districts. At the end of
a campaign, each province holds an evaluation meeting
during which a final synthesis of district vaccination cov-
erage is performed and transmitted to the central level.
We used WHO guidance documents [21,22] to develop
written procedures for yellow fever surveillance, including
case definition, case investigation forms, and instructions
for specimen collection and transport, and outbreak
investigation and response. This guidance material served
as the basis for large-scale training in 2002 of central, pro-
vincial, district and health centre personnel using a snow-
ball approach. These training sessions were also used as
refresher courses for surveillance of other EPI diseases
(acute flaccid paralysis [poliomyelitis], measles and neo-
natal tetanus). Following the training, case-based surveil-
lance of suspected yellow fever cases was initiated in the
country in January 2003. Since then, basic demographic
and clinical information as well as one venous blood
specimen are obtained from each suspected yellow fever
case (i.e. a person who presents with fever followed by
jaundice within two weeks of onset of fever). The blood
specimen is well centrifuged and the resulting serum sent
to the laboratory within three days of collection. Each
blood specimen is tested for yellow-fever-specific IgM
antibodies by use of rapid IgM enzyme-linked immuno-
assay kits. A confirmed yellow fever case is defined as a
suspected case with either laboratory confirmation via the
IgM assay or epidemiological linkage to a laboratory-con-
firmed case. Currently, one confirmed case of yellow fever
is considered an outbreak. Three key indicators are used to
assess yellow fever case-based surveillance, i.e. the propor-
tion of reported yellow fever cases with a blood specimen,
the proportion of districts with at least one blood speci-
men in a year and the proportion of yellow fever out-
breaks investigated with district outbreak reports sent to
the central level. The target value for each indicator is a
proportion of at least 80%.
Regular supportive supervision and meetings are used to
monitor and improve the quality of data collection, anal-
ysis and reporting during both routine and supplementary
activities. We have analysed the yellow fever vaccination
and surveillance data reported to the EPI Central Techni-
cal Group in the Ministry of Public Health in Yaoundé
from 2003 to 2006, and discussed the sustainability of
yellow fever control activities in the country.
Results
Figure 1 shows the national yellow fever vaccination cov-
erage and the coverage gap for yellow fever and measles
vaccines in Cameroon from 2004 to 2006. Routine child-
hood yellow fever vaccination coverage rose from 58.7%
in 2004 to 72.2% in 2006. Yellow fever vaccination cover-
age lagged behind measles vaccination coverage by more
than five percentage points in 2004. From this timid start,
the country rapidly achieved parity between yellow fever
and measles vaccination coverage (i.e. not more than five
percentage point difference between yellow fever and
measles vaccination coverage) in 2005 and has since
maintained this performance level. In addition, there was
wide variation in yellow fever vaccination coverage levels
across the country in 2004 (Figure 2) with only 6 out of
10 provinces achieving parity in yellow fever and measles
Routine childhood vaccination coverage for yellow fever vac- cine and the coverage gap for measles and yellow fever vac- cines in Cameroon, 2004–2006 Figure 1
Routine childhood vaccination coverage for yellow 
fever vaccine and the coverage gap for measles and 
yellow fever vaccines in Cameroon, 2004–2006. M, 
measles; YF, yellow fever.
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vaccination coverage. However, yellow fever vaccination
coverage levels have since improved with all 10 provinces
achieving parity between yellow fever and measles vac-
cines since 2005 (Figure 2).
In 2004, 16 high-risk districts with an estimated popula-
tion of 1,848,158 people aged six months and above were
selected for mass preventive vaccination campaigns. Each
of the 16 districts was considered high risk either because
it had reported a yellow fever outbreak within the last two
decades or it has a large urban population in close prox-
imity to a district that has recently reported an outbreak.
The first phase of the preventive campaigns took place
from 13 to 22 November 2006 in six districts (Figure 3),
with vaccines supplied free from the GAVI Alliance yellow
fever vaccine stockpile. During these supplementary
immunisation activities, particular emphasis was placed
on maintaining the cold chain, ensuring safe injection
practices and surveillance of adverse events following
immunisation (AEFIs). Vaccinators and supervisors were
trained to recognise and report all adverse events in vacci-
nated persons following immunisation, and forms for
reporting these AEFIs were distributed to all vaccination
posts and health centres. During the 10 days of the vacci-
nation campaigns, 752,195 (92.8%) people were vacci-
nated by 247 vaccination teams. The wastage rate for
vaccines was 4.6% and that for safety boxes was 0.9%.
Medical incidents were reported in 13 persons who had
received the yellow fever vaccine (nine cases of injection
site pain and swelling in the Ngaoundéré Urban health
district and four cases of skin rash in the Yoko health dis-
trict). None of these AEFIs was serious (i.e. life-threaten-
ing or required hospitalisation) and each was well
managed by local health staff. There was high-level polit-
ical commitment to these preventive vaccination cam-
paigns which were officially launched in the Messamena
health district of the East Province by the national Minis-
ter of Public Health, in the presence of WHO and UNICEF
country representatives and high-ranking administrative
and political leaders of the province. Following the suc-
cessful implementation of the supplementary immunisa-
tion activities in the six districts, Cameroon plans to re-
assess the risk of yellow fever outbreaks in the country
[23] in 2007 in order to update the list of high-risk dis-
tricts for the second phase of the preventive supplemen-
tary immunisation activities scheduled for 2008.
Table 1 shows the performance of yellow fever case-based
surveillance in Cameroon. Since 2003 yellow fever sur-
veillance in the country has been fully integrated with sur-
veillance activities for acute flaccid paralysis and measles
[16,18,24]. The surveillance of all three vaccine-preventa-
ble diseases share the same personnel and infrastructure at
all levels of Cameroon's health care system, including per-
sonnel for reporting and investigation of suspected cases,
specimen transport, and data management systems. The
proportion of districts with at least one suspected yellow
fever case per year increased from 31.4% in 2003 to 68.2%
in 2006. Blood specimens were taken from all suspected
yellow fever cases (within 14 days of onset of symptoms)
and transported to and tested for yellow fever IgM anti-
bodies at the Centre Pasteur in Yaoundé, Cameroon. All
blood specimens that tested positive for IgM antibodies at
the Centre Pasteur in Yaoundé were sent to the Pasteur
Institute in Dakar, Senegal, for confirmatory tests. Cases
of yellow fever were confirmed in Bafia, Méri and Ntui in
Maps of Cameroon showing the coverage gap between routine yellow fever and measles vaccination at sub-national level,  2004–2006 Figure 2
Maps of Cameroon showing the coverage gap between routine yellow fever and measles vaccination at sub-national level, 
2004–2006.
2004 2005  2006 
  Coverage gap 0.0-5.0% 
   Coverage gap 5.01-10.00% 
  Coverage gap > 10.00% BMC Medicine 2008, 6:3 http://www.biomedcentral.com/1741-7015/6/3
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2003, Ngaoundéré Rural in 2004, Yoko in 2005 and Mes-
samena in 2006 (Table 1). Reactive mass vaccination cam-
paigns were conducted in Bafia (in January 2004) and
Méri (in April 2004) health districts several months after
confirmation of the yellow fever cases owing to con-
straints in mobilising the necessary resources. For the
same reasons, vaccination campaigns were not organised
in response to the epidemics in Ntui, Ngaoundéré Rural
and Yoko health districts. However, these health districts
were among the districts that conducted preventive mass
vaccination campaigns in November 2006. The mass vac-
cination campaign in response to the epidemic in Messa-
mena health district was also integrated into the
preventive vaccination campaigns in high-risk districts in
November 2006. The vaccination coverage was 93.8%
(25,425/27,103) in Bafia and 84.5% (34,658/41,000) in
Meri. In both districts, the mean wastage rates for vaccines
and injection material were less than 5% and there were
no reports of AEFIs.
Discussion
The government of Cameroon, with assistance from her
development partners, has since 2003 been implementing
strategies both to prevent yellow fever outbreaks and to
detect and respond appropriately to the outbreaks when
they occur. Routine yellow fever vaccination coverage has
improved dramatically with the country achieving parity
between yellow fever and measles vaccination coverage
within a year of introducing the yellow fever vaccine into
the routine childhood immunization schedule. In addi-
tion, districts at high risk of yellow fever outbreaks were
identified for preventive supplementary immunisation
activities. The first phase of the latter was very successful
in terms of vaccination coverage (93%) and quality (i.e.
no serious AEFI was reported). In addition, the case-based
yellow fever surveillance system is being used to update
the list of high-risk districts. However, the major con-
straint has been responding promptly to a declared yellow
fever outbreak. Ideally, a mass vaccination campaign
should be organised within days of confirming a yellow
fever epidemic in order to contain the outbreak. This has
not been the case, owing to difficulties in rapidly mobilis-
ing resources amidst other competing health priorities.
However, Cameroon has made remarkable preliminary
progress in controlling yellow fever in recent years. The
challenge now is to complete the planned preventive mass
vaccination campaigns within schedule and to increase
and maintain high routine vaccination coverage. In addi-
tion, measures have to be taken to improve and maintain
high-quality case-based surveillance in all health districts,
promptly plan and conduct reactive mass campaigns
when outbreaks occur and continuously monitor AEFIs.
Even though our team and other investigators in Africa
[25] did not find serious adverse events following yellow
fever immunisation, AEFIs have recently become a big
issue in South America and non-endemic countries where
travellers are immunized against yellow fever [26,27]. In
the early years of yellow fever vaccine production, post-
vaccination encephalitis was common but such events
were markedly reduced after the adoption of seed lot
manufacturing in 1941 and the restriction of vaccination
to persons older than six months of age after 1969
[27,28]. Vaccine-associated neurotropic disease is cur-
Districts that conducted mass yellow fever vaccination cam- paigns in Cameroon in November 2006 Figure 3
Districts that conducted mass yellow fever vaccina-
tion campaigns in Cameroon in November 2006. 
Ngdéré, Ngaoundéré; Rur, Rural; Urb, Urban.
Meri
Maroua Rur
Ngdéré Urb
Ngdéré Rur
Yoko
Messamena
Ntui
Table 1: Yellow fever case-based surveillance in Cameroon, 2003–2006
Year Number 
of districts
Districts reporting at 
least one suspected case
Number of suspected 
cases reported
Blood specimens 
collected
Confirmed cases Districts with 
confirmed cases
nn % nn % n %
2003 144 52 36.1 156 156 100 3 1.3 Bafia, Méri, Ntui
2004 159 80 50.3 434 434 100 2 0.5 Ngaoundéré Rural
2005 159 88 55.3 831 831 100 2 0.2 Yoko
2006 167 114 68.2 859 859 100 1 0.2 MessamenaBMC Medicine 2008, 6:3 http://www.biomedcentral.com/1741-7015/6/3
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rently estimated to occur at a frequency of 4 per 1,000,000
doses [29]. Within the past decade, a more severe adverse
event following yellow fever immunisation emerged [30-
32]. In 2001, seven cases of severe acute viscerotropic dis-
ease following immunisation were reported; six of these
were fatal [30-32]. This condition mimics severe yellow
fever and is estimated to occur at a frequency of 3 per
1,000,000 doses [29]. The mechanism underlying vac-
cine-associated neurotropic or viscerotropic events is
poorly understood. These events could be a result of vac-
cine virus reversion (or mutation) to wild-type virulence
or a result of host-specific factors [27,28]. Whatever the
underlying cause, each AEFI requires a thorough investiga-
tion to establish whether it is caused by the vaccine itself,
by an error in the administration of the vaccine or not
related to the vaccine or administration (i.e. its occurrence
merely coincided with vaccine administration). AEFIs
may upset the public and lead to refusal of further immu-
nisation. If this were allowed to occur, hundreds of thou-
sands of people will continue to contract yellow fever each
year and tens of thousands of these will die. Therefore,
surveillance of AEFIs helps to preserve public confidence
in immunisation programmes and should be an integral
part of all yellow fever immunisation programmes.
Opportunities for improving yellow fever control in Cam-
eroon include the recently formed Yellow Fever Initiative
[10] and the high-level political commitment to the con-
trol of vaccine-preventable diseases in the country
[16,19]. The Yellow Fever Initiative will assist 12 priority
countries in West Africa, including Cameroon, to conduct
mass preventive vaccination campaigns targeting 48 mil-
lion people between 2007 and 2010. These preventive
campaigns should dramatically reduce the yellow fever
disease burden in these countries, just as similar cam-
paigns did for measles [33-35]. Later in 2007, Cameroon
will conduct a yellow fever risk analysis using the WHO
decision-making tool for preventive immunization cam-
paigns [23] in order to update the list of high-risk districts
for preventive mass campaigns next year.
The long-term strategy for yellow fever control in the
country, as elsewhere, remains high routine childhood
vaccination coverage. High vaccination coverage should
be attained and maintained among infants, before their
first birthday, in every district. The operational strategies
for achieving and sustaining high routine vaccination cov-
erage (90% or more) in each successive birth cohort
include fostering high-level political commitment,
improving the planning and monitoring of immunisation
services at all levels, community mobilisation, efficient
coordination of current immunisation partners and
mobilisation of additional funding for immunisation
services.
The EPI was restructured in 2002 and is now a prominent
organisational structure in the Ministry of Public Health,
and the government is committed to sustaining routine
vaccination services by making vaccines and vaccination
material (vaccination cards, vaccination registers, syringes
and safety boxes) permanently available at all levels of the
health system. The restructured programme focuses maxi-
mum financial and technical support at the district level.
Districts with low vaccination coverage are identified and
given technical assistance in planning and monitoring
vaccination activities. Emphasis is placed on supportive
supervision, regular meetings to discuss data, use of data
for programmatic action and regular feedback. Novel
operational strategies developed at district and health
facility levels include keeping log books in all villages for
a census of all newborns and conducting special immuni-
sation days in hard-to-reach areas, those without health
units and or health workers and those with low vaccina-
tion coverage. Since vaccination coverage is strongly asso-
ciated with socio-economic status in Cameroon [36],
communication and social mobilisation efforts that
accompany and support vaccination delivery have been
adapted to each milieu. Permanent community dialogue
structures have been established in all health districts and
efforts are made to reach poorly educated mothers by dis-
seminating information through women's associations
and community opinion leaders, resulting in increased
demand for vaccination services [19].
Conclusion
In conclusion, amidst other competing health priorities,
Cameroon is using experience gained from controlling
other vaccine-preventable diseases to plan and implement
evidence-based strategies for preventing yellow fever out-
breaks and for detecting and responding to outbreaks
when they occur.
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